IMMUNOHISTOCHEMISTRY, BCL-6

The Immunohistochemistry (IHC) – BCL-6 test is a specialized diagnostic test used to detect BCL-6 (B-cell lymphoma 6) protein expression in tissue samples. BCL-6 is a transcription factor that plays an important role in the development and regulation of germinal center B-cells, which are essential components of the immune system.

This test is widely used in hematopathology to diagnose and classify B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Detecting BCL-6 expression helps pathologists determine whether lymphoma cells originate from germinal center B-cells and assists in accurate lymphoma subtype classification.

The BCL-6 marker is especially valuable in distinguishing germinal center B-cell-like (GCB) lymphomas from non-germinal center subtypes, which can influence prognosis and treatment planning.

The BCL-6 IHC test is often performed alongside other lymphoma markers such as CD10, BCL2, MUM1, CD20, Ki-67, and CD3 for a complete diagnostic profile.

Benefits of the Test

The BCL-6 test offers several important clinical benefits:

• Detects BCL-6 protein expression accurately
• Helps classify B-cell lymphoma subtypes
• Identifies germinal center origin
• Supports prognosis assessment
• Assists in treatment planning
• Improves diagnostic precision

This test is essential for accurate lymphoma diagnosis and classification.

Why Doctors Recommend This Test

Doctors recommend the BCL-6 test when lymphoma diagnosis or classification is required.

It is commonly advised for:

• Suspected B-cell lymphoma evaluation
• Classification of diffuse large B-cell lymphoma
• Follicular lymphoma diagnosis
• Germinal center phenotype identification
• Advanced hematopathology assessment

The results help hematologists and oncologists select appropriate treatment strategies.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected lymph node biopsy or tissue specimens.

Normal Reporting Time

The usual turnaround time for the BCL-6 IHC test is 3 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with suspected lymphoma
• Individuals requiring lymphoma subtype classification
• Patients with abnormal lymph node biopsy findings
• Cases needing germinal center origin identification
• Oncology patients requiring personalized treatment planning

The IHC BCL-6 test is an essential diagnostic tool in hematopathology. It supports precise lymphoma classification, improves diagnostic confidence, and helps guide targeted treatment decisions for better patient outcomes.